177Lu-Dotatate for Midgut Neuroendocrine Tumors

Nuriye Y Ozdemir¹, Suheyla A Arslan^{1

2}, Mehmet A Sendur¹

Affiliations

Comment

Nuriye Y Ozdemir et al. N Engl J Med. 2017.

. 2017 Apr 6;376(14):1391.

doi: 10.1056/NEJMc1701616.

Nuriye Y Ozdemir¹, Suheyla A Arslan^{1

2}, Mehmet A Sendur¹

No abstract available

Comment in

177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, Krenning E. Strosberg J, et al. N Engl J Med. 2017 Apr 6;376(14):1391-2. doi: 10.1056/NEJMc1701616. N Engl J Med. 2017. PMID: 28379808 No abstract available.

Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.